NEW YORK – Prenosis said on Wednesday it is expanding a partnership with Roche Diagnostics to accelerate and improve the detection of sepsis.
The two firms began collaborating in 2020, and as part of the expanded agreement, Chicago-based Prenosis will expand its NOSIS dataset. The partners will also work to gain clearance from the US Food and Drug Administration for the Prenosis Sepsis Immunoscore and Roche Elecsys IL-6 assay. Roche's test, which measures levels of interleukin 6, received Emergency Use Authorization from the FDA in June 2020 to identify severe inflammatory response in COVID-19 patients.
The NOSIS dataset, Prenosis said, is a hybrid biomarker-clinical dataset for sepsis care, while the Immunoscore algorithm leverages Elecsys IL-6 and other sepsis biomarkers and clinical risk parameters to predict, diagnose, and treat sepsis at earlier stages than with other clinical tools.
According to a Prenosis spokesman, Roche's financial contribution to the partnership is $6 million.